As one of the leading dating sites, eHarmony thinks a lot about relationships and compatibility. The company recently released a report called "The Happiness Index: Love and Relationships in America" and eHarmony CEO Grant Langston discusses the results with Alyssa Julya Smith in Los Angeles. Langston reveals that the study shows that 64% of Americans are "very happy" in their relationships with a partner or spouse. The results also revealed that millennials reported being the most happy, and were the most likely to value communication in their relationships. Langston also reveals that eHarmony is responsible for 4% of American marriages, and more people are signing up for the dating service every year. He says that when people are ready to have a long and meaningful relationship, eHarmony is where they go, because of the company's focus on compatibility.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More